ViroGates A/S Total Liabilities
ViroGates A/S total liabilities. Based on the latest financial reports, ViroGates A/S (VIRO) has total liabilities worth Dkr9.98 Million DKK (≈ $1.56 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See ViroGates A/S liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Total Liabilities of ViroGates A/S (2015–2025)
Total liabilities of ViroGates A/S from 2015 to 2025. This chart illustrates how ViroGates A/S's total liabilities have evolved over time, based on quarterly financial data. See ViroGates A/S free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
ViroGates A/S Competitors by Total Liabilities
The table below lists competitors of ViroGates A/S ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Healthcare Triangle Inc
NASDAQ:HCTI
|
USA | $24.63 Million |
|
Charn Issara Development Public Company Limited
BK:CI
|
Thailand | ฿8.16 Billion |
|
Cofidur SA
PA:ALCOF
|
France | €41.36 Million |
|
Tasman Resources Ltd
AU:TAS
|
Australia | AU$227.26K |
|
Biomaxima
WAR:BMX
|
Poland | zł30.50 Million |
|
Oakley Capital Investments Limited
LSE:OCI
|
UK | GBX227.55 Million |
|
Complii Fintech Solutions Ltd
AU:CF1
|
Australia | AU$2.49 Million |
Liability Composition Analysis (2015–2025)
This chart breaks down ViroGates A/S's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see VIRO asset base.
Liquidity & Leverage Metrics
ViroGates A/S Total Liabilities Ratios Explained
ViroGates A/S total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.82 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.59 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ViroGates A/S's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ViroGates A/S (2015–2025)
The table below shows the annual total liabilities of ViroGates A/S from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Dkr11.19 Million ≈ $1.75 Million |
+62.94% |
| 2024-12-31 | Dkr6.87 Million ≈ $1.07 Million |
-9.05% |
| 2023-12-31 | Dkr7.55 Million ≈ $1.18 Million |
+420.19% |
| 2022-12-31 | Dkr1.45 Million ≈ $227.02K |
-61.85% |
| 2021-12-31 | Dkr3.80 Million ≈ $595.01K |
-45.14% |
| 2020-12-31 | Dkr6.93 Million ≈ $1.08 Million |
+135.62% |
| 2019-12-31 | Dkr2.94 Million ≈ $460.30K |
+21.97% |
| 2018-12-31 | Dkr2.41 Million ≈ $377.37K |
+21.76% |
| 2017-12-31 | Dkr1.98 Million ≈ $309.94K |
-34.23% |
| 2016-12-31 | Dkr3.01 Million ≈ $471.25K |
-0.46% |
| 2015-12-31 | Dkr3.03 Million ≈ $473.44K |
-- |
About ViroGates A/S
ViroGates A/S, an in vitro diagnostics company, develops and sells blood tests for measuring chronic inflammation for the healthcare sector. It offers suPARnostic TurbiLatex, a CE-IVD approved particle-enhanced turbidimetric immunoassay for quantitative measurement of suPAR in human plasma; suPARnostic AUTO Flex ELISA kit, a fully quantitative immunoassay designed for accurate and reliable measur… Read more